This weekend, our team will be at the 2025 @HAE Regional Conference EMEA in Rome, Italy. We look forward to gathering insights from the #HAE patient community and physicians. https://t.co/vcR5kCeW7q

🔴 📣 Watch this month’s new US HAEA Treatment Education Series Webinar: “Living with HAE: Insights and the HAE Community Survey.” Now on-demand! Watch here: https://t.co/JtnXwNQGAg #HAEA #HAEAwareness #HAEATreatmentSeries #HereditaryAngioedema #HAECommunity

Members from Intellia’s team will be at the @HFSA Annual Scientific Meeting this weekend in Minneapolis. We look forward to connecting and the insightful conversations!

$NTLA News: Intellia announces positive longer-term data from the ongoing Phase 1 trial in #ATTRamyloidosis with polyneuropathy and the company’s latest publication in @NEJM. Read the press release: https://t.co/T94tQhVdEN

The Intellia team is gearing up for the 5th International #ATTR #Amyloidosis Meeting for Patients and Doctors in Baveno, Italy, Sept. 25-26. Press Release: https://t.co/9kzvaYLyBG HCPs: Be sure to tune into our presentation on Thursday and stop by our booth to learn even more

$NTLA News: We’re excited to share Intellia has completed enrollment in HAELO, our Phase 3 trial for the treatment of #hereditaryangioedema. Read the press release: https://t.co/KLrvA4Phik

Later today, Intellia’s SVP, Technical Operations, Kristy Wood, Ph.D., will be delivering a keynote at Cell & Gene Therapy International: From Breakthrough Science to Life-Changing Treatments in Boston. #CGTI @CellTherapyIC

Unpredictable. Mentally exhausting. These are some of the words used to describe a day in the life as someone living with #hereditaryangioedema. Through our research, we’ve learned people living with #HAE face daily challenges – physical or emotional. At Intellia, our mission

Starting tomorrow, members from Intellia’s management team will be heading to two investor conferences this month: > @WellsFargo Healthcare Conference – Boston > Bernstein Healthcare Forum – New York We look forward to connecting and sharing Intellia’s progress.

This weekend, members from our #ATTR team will be at the #ESCCongress. HCPs: Don’t miss our symposium on Monday, chaired by Dr. Julian Gillmore, discussing all things #amyloidosis and advancements in the field. #ESCCongress #WCCardio

Intellia is committed to fostering relationships with patient advocacy organizations to gain a comprehensive understanding of various conditions and its impact on patients and their families. Today, we share a glimpse into what life can look like for those living with

As part of our efforts to bring Intellia’s promising therapies to those in need, we’ve been building out our commercial and medical functions. They each play a pivotal role in shaping our strategy and advancing our mission. Hear what some of our leaders have to say. #OneIntellia

$NTLA announces recent company progress and second quarter financial results. Read the press release: https://t.co/uyrNUoLgIr

This week, Intellia director, RNA technologies, Weijun Chen, Ph.D., will be presenting at @HansonWade’s 5th mRNA-Based Therapeutics Summit in Boston on July 23 at 1:15 p.m. ET. Learn more about Intellia’s approach to #geneediting: https://t.co/vcR5kCeW7q

Big thank you to @US_HAEA for hosting a great conference and those who visited our booth. We appreciated all the insightful conversations and highlighting our progress. Until next time!

We’re looking forward to the 2025 @US_HAEA National Summit this weekend in Baltimore. HCPs: Intellia will present three posters from our #hereditaryangioedema program on Friday, July 11. See you there! #USHAEANationalSummit #HAE

We’re excited to share Intellia will present positive three-year data from our Phase 1 trial in #hereditaryangioedema at today’s @EAACI_HQ Congress and that our global Phase 3 HAELO trial has concluded screening ahead of schedule. Read the press release: https://t.co/dRsUrJYSBd

Tomorrow, Intellia Senior Director, Yong Zhang, Ph.D., will take the stage at the 7th Allogeneic Cell Therapies Summit in Boston, where he will discuss Intellia’s allogeneic platform as an approach to #celltherapy. https://t.co/vcR5kCeW7q

Our #HAE team is off to Budapest for the C1-Inhibitor Deficiency & Angioedema Workshop. HCPs: tune into our oral and poster presentations this weekend about our research and Phase 3 HAELO study design for #hereditaryangioedema. https://t.co/IsuJp3NySq